Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.

You may also be interested in...

A Closer Look: Ambrx Doubles Down In China With Hisun Deal

San Diego-based Ambrx is aggressively striking deals with companies in China. PharmAsia News takes a closer look at a recent deal with Hisun and adds background to its growing ties to Big Pharma.

Deals Of The Week: Will Heated Competition To Buy Out Ache Laboratorios Muddy The Brazilian Waters?

Pfizer, Novartis and Abbott reportedly are battling to buy out family-owned Ache, Brazil’s leader in prescription drug sales. Plus deals involving AstraZeneca and AlphaCore, Pfizer and Bind Therapeutics and Merck and Ra Pharma.

Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal

The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts